Directors’ Dealings
Directors Receive Shares in Lieu of Fees

London and New York, 16 October 2009 - Amphion Innovations plc (LSE: AMP), the developer of medical and technology businesses, today announces that, at a Board meeting held today, the Company has issued 302,861 ordinary shares, representing 0.23% of the enlarged issued share capital, to certain of its Board members, in lieu of their directors’ fees for the third quarter to September 2009, priced at 14.85p, being the average of the closing mid-market price for the five days leading up to the market close on 30 September 2009. Following this issue, the directors’ shareholdings in the Company are as follows:

Director Number of New Shares Price Total Shareholding Percentage of voting rights
Richard Mansell-Jones 164,063 14.85 3,212,680 2.43%
Anthony Henfrey 31,250 14.85 1,159,485 0.88%
R. James Macaleer 57,548 14.85 22,501,692 17.01%
Gerard Moufflet 50,000 14.85 100,000 0.08%

In addition, Board members Richard Mansell-Jones and Anthony Henfrey have used part of their directors’ fees for the third quarter to 30 September 2009, to subscribe to the convertible promissory note offering for a total of £8,591. 

Director New Promissory Note Total Holding of Promissory Notes Conversion Price New Warrants Total Warrants
Richard Mansell-Jones £4,686 £16,998 18p 5,202 18,868
Anthony Henfrey £3,905 £10,061 18p 4,335 11,168

The Convertible Promissory Notes are convertible between 31 December 2008 to 31 December 2013 into fully paid Ordinary Shares of 1 pence each in the capital of the Company at a conversion price of 18 pence per Ordinary Share and pay interest of 7 per cent annually until conversion. In addition, for each Note issued, the Company also issued 1.11 warrants to each subscriber of the Notes, a ratio of one warrant for every five shares issuable upon conversion. Each warrant will entitle the holder to subscribe for one Ordinary Share at 20 pence per Ordinary Share.
Admission of the 302,861 new ordinary shares, ranking pari passu, is expected on 21 October 2009. Following this allotment the total issued share capital of the Company will increase to 132,258,897 ordinary shares.

For further information please contact

Amphion Innovations plc
Charlie Morgan, Director of Communications                      
+1 (212) 210 6224

Cardew Group

Tim Robertson/ Jamie Milton/ Matthew Law                         
+44 20 7930 0777

Charles Stanley
(Nominated Adviser)
Mark Taylor/ Freddy Crossley/Jen Boorer                            
+44 20 7149 6000

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has a significant shareholding in ten Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
On the web: